haematology
Coagulation

Dabigatran reversal agent stacks up in the real world

The reversal agent for dabigatran (Idarucizumab, Praxbind) can quickly halt the effect of the novel oral anticoagulant in patients with life threatening bleeding or in those who need urgent surgery, the final data from REVERSE-AD reveals. The findings confirm the results of an interim analysis that saw the reversal agent gain regulatory approval last year. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic